Gene change and methotrexate response in psoriasis
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This study looks at a specific gene change (called TRAF3IP2) in people with psoriasis or psoriatic arthritis who are about to start methotrexate. The goal is to see if the gene affects how well the treatment works or if it causes side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have psoriasis or psoriatic arthritis that is moderate to severe (your doctor will check your PASI score).
- You are about to start methotrexate treatment.
- You do not have other autoimmune diseases (like rheumatoid arthritis or lupus).
- You are not pregnant or breastfeeding, and you have no liver or kidney problems.
- You have not had genetic testing for this specific gene change before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a specific gene (Card14) in Egyptian patients with psoriasis or psoriatic arthritis. It may help understand why some people get these conditions and how they could be treated better.
This study compares two oral pill treatments—methotrexate and tofacitinib—for people with chronic plaque psoriasis that is moderate to severe and hasn't responded well to creams. The goal is to see which pill works better at clearing skin.
This pilot study tests whether adding probiotics to standard methotrexate treatment improves symptoms in people newly diagnosed with chronic plaque psoriasis. It aims to see how the gut microbiome affects treatment response.
This study tests whether increasing the dose of methotrexate or switching from pills to injections can better control rheumatoid arthritis symptoms. It aims to find the best way to use this common medication to reduce joint pain and swelling.
This study looks at how well methotrexate injections work in people with rheumatoid arthritis. It is designed for patients who are starting or changing to this type of methotrexate treatment.
This trial tests if a treatment can prevent joint damage in people recently diagnosed with psoriatic arthritis. It compares a standard medication (methotrexate) with or without a newer biologic drug (adalimumab) to see which is better at stopping the disease from causing lasting harm.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.